Navigation Links
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Date:5/5/2008

ncial rights, moved forward with GSK's announcement of plans to advance darapladib to Phase 3 development for the treatment of atherosclerosis."

FINANCIAL RESULTS

HGS reported increased revenues for the quarter ended March 31, 2008 of $12.3 million, compared with revenues of $9.3 million for the same period in 2007. Revenues included $8.9 million recognized from the Albuferon agreement with Novartis, and $1.6 million in revenue recognized from the LymphoStat-B agreement with GlaxoSmithKline (GSK).

The Company reported a net loss for the quarter ended March 31, 2008 of $46.9 million ($0.35 per share), compared with a net loss for the first quarter of 2007 of $51.0 million ($0.38 per share).

Net cash burn for the three months ended March 31, 2008 totaled $36.1 million, net of $47.3 million received from Teva Pharmaceutical Industries Ltd., in partial payment for CoGenesys, Inc. stock previously owned by HGS.

As of March 31, 2008, cash and investments totaled $591.3 million, of which $519.0 million is unrestricted and available for operations. This compares with cash and investments totaling $603.8 million, of which $532.9 million was unrestricted and available for operations, as of December 31, 2007.

"Our cash position remains strong and our 2008 net cash burn is on track for $135-155 million as previously guided," said Tim Barabe, Senior Vice President and Chief Financial Officer, HGS.

HIGHLIGHTS OF RECENT PROGRESS

LymphoStat-B(R): Phase 3 Enrollment for BLISS-52 Completed; First Phase 3 Data Expected by Mid-2009

In April 2008, HGS announced the completion of enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE). Completion of enrollment for the other pivotal Phase 3 trial, BLISS-76, is expected by the end of summer 2008. HGS now expects to have the first Phase 3 data for LymphoStat-B ava
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
2. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
3. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Human Genome Sciences Advances Oncology Portfolio
6. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
7. Human Pheromone Sciences Announces Quarterly and Full Year Results
8. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Kennedy Joins with State Biotech Leaders to ... Research and Development while Boosting Rhode Island,s ... ,, PROVIDENCE, R.I., Dec. 14 ... in research, medicine and biotechnology gathered today ... discuss the importance of medical innovation in ...
(Date:12/14/2009)... 14 Boston Scientific Corporation (NYSE: ... offering of $2 billion aggregate principal amount of its ... The public offering consists of $850 million of 4.50 ... percent notes due January 2020 and $300 million of ... plans to use the net proceeds for general corporate ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/14/2009)... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ... ... MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based thermoforming ... Tester – helping Brookfield move from sheet metal to a ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
... Calif., April 7, 2008 InterWest Partners,announced ... to the venture capital firm,s Advisory Committee: ... Leroy Hood, and,former FDA commissioner Dr. Mark ... experienced professional advisors, providing strategic guidance,to the ...
... Genmab A/S Summons Annual General Meeting Summary: ... COPENHAGEN, Denmark, April 7 Genmab A/S (OMX:,GEN) summon ... 3:00,pm CEST at the Radisson SAS Scandinavia Hotel, Amager Boulevard ... the Board of Directors on the Company,s activities during,the year., ...
... A modern computer contains two different types of components: ... which perform logic operations. A University of Missouri researcher, ... to combine these two functions in a single hybrid ... memory and logical functions and is expected to permit ...
Other Biology Technology:Prestigious Scientific Leaders Join InterWest Advisory Committee 2Prestigious Scientific Leaders Join InterWest Advisory Committee 3Prestigious Scientific Leaders Join InterWest Advisory Committee 4Genmab A/S - Notice to Convene Annual General Meeting 2Genmab A/S - Notice to Convene Annual General Meeting 3Genmab A/S - Notice to Convene Annual General Meeting 4Genmab A/S - Notice to Convene Annual General Meeting 5Genmab A/S - Notice to Convene Annual General Meeting 6Genmab A/S - Notice to Convene Annual General Meeting 7Hybrid computer materials may lead to faster, cheaper technology 2
(Date:12/11/2009)... temperature variability and circulation system could help improve projections ... affected more by surface warming than previously thought, and ... such as sea level rise and ice volume changes. ... to result in a more vigorous deep ocean circulation ... large quantities of warm water, with possible impacts including ...
(Date:12/11/2009)... traditionally been limited by the seasons, particularly ... be short. Thanks to researchers and fruit ... that offer growers the ability to produce ... for both producers and consumers. Fresh examples ... "primocane-fruiting", which bear fruit on current-season canes, ...
(Date:12/11/2009)... is available in German . ... more plant introductions than extinctions, plant communities of ... same species are occurring more frequently, whereas rare ... the biological communities that are becoming increasingly similar, ... processes have led to a loss of uniqueness ...
Breaking Biology News(10 mins):New discoveries could improve climate projections 2New management methods extend blackberry season 2Europe's flora is becoming impoverished 2Europe's flora is becoming impoverished 3GeoVax Labs Inc Provides Clinical Studies Update 13389 1GeoVax Labs Inc Provides Clinical Studies Update 13389 2GeoVax Labs Inc Provides Clinical Studies Update 13389 3GeoVax Labs Inc Provides Clinical Studies Update 13389 4GeoVax Labs Inc Provides Clinical Studies Update 13389 5Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 53728 1Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 53728 2Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 53728 3Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 53728 4Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 53728 5The Organic Center Refutes Misleading Nutritional Claims Made by United Kingdoms Food Standards Agency 28FSA 29 in Agency Report on Health Value of O 53724 1The Organic Center Refutes Misleading Nutritional Claims Made by United Kingdoms Food Standards Agency 28FSA 29 in Agency Report on Health Value of O 53724 2
... a conversation with someone, we not only hear what they say, ... can be direct or shifty. “Reading?these facial expressions gives context and ... be presented May 5 at the International Meeting for Autism Research ... can’t do this. They hear and they see, of course, but ...
... Northwest National Laboratory geologists have put out a call ... parts of extinct mammoths left by massive Ice Age ... cases whole skeletons of Mammathus columbi, the Columbian mammoth, ... the Yakima, Columbia and Walla Walla valleys in southeastern ...
... novel therapies to prevent cancer spread, or metastasis, researchers at ... have targeted a sugar that supports blood vessel growth in ... May 7 on-line issue of Journal of Cell Biology. ... death and an area where novel therapies to block metastasis ...
Other Biology News:A frown or a smile? Children with autism can't discern 2An ancient bathtub ring of mammoth fossils 2Targeting sugar on blood vessels may inhibit cancer growth 2
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
...
... Mammalian Protein Extraction Reagent is ... solution that means no scraping, ... sonication! With M-PER Reagent, rapid ... minutes at room temperature, yielding ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
Biology Products: